Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium

C. Rinciog,A. Diamantopoulos,A. Gentilini,Benjamin Bondue,Caroline Dahlqvist,Antoine Froidure,Wim A. Wuyts,S Soulard

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium

2020

C. Rinciog
A. Diamantopoulos
A. Gentilini
Benjamin Bondue
Caroline Dahlqvist
Antoine Froidure
Wim A. Wuyts
S Soulard

Background Nintedanib (Ofev®) and pirfenidone (Esbriet®) are recommended by international guidelines as treatment options for idiopathic pulmonary fibrosis (IPF).

Keywords:

Cost-effectiveness analysis
Idiopathic pulmonary fibrosis
Gastroenterology
Internal medicine
Pirfenidone
Nintedanib
Medicine
Intensive care medicine
economic analysis
treatment options
Discontinuation
Exacerbation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations